Comparing the long-term and real world effectiveness of initial management strategies for DCIS
Use data from the DCIS study (initially funded via the Cancer Research Network) to generate real world evidence regarding risk of recurrence and treatment for recurrence after initial diagnosis and treatment. Specifically, we will 1) Determine type of surgery and the rate of complications from surgery including reconstructive surgery after recurrence, 2) Use the variables in the study to create a personalized risk score for use in predicting the rate of recurrence in an individual patient and 3) Study the timing, side effects, compliance of tamoxifen therapy and the relationship between duration of tamoxifen on timing of local recurrence and the use of tamoxifen at diagnosis of DCIS recurrence.
Funder: Agency for Healthcare Research and Quality
Principal Investigator: Habel, Laurel
Developing an HMORN Collaboratory
In collaboration with the National Institutes of Health, the Collaboratory will strengthen the HMORN research ceners' partnerships with their parent health systems, enabling more robust evidence translation capabailities.
Funder: National Cancer Institute
Principal Investigator: Habel, Laurel
Statins & Lymphoid Malignancy Risk in a Large Multi-site Population-based Cohort
In multiple sites participating in the CRN, our specific goals are to: 1. Quantify the association between statin use and the risk of a lymphoma, overall and by specific statin and lymphoma subtype. Comparison with use of other antilipemics (i.e., anion exchange resins, fibrates, nicotinic acid, and ezetimib) will also be assessed as an internal comparison. 2. To assess the association between use of statins among patients at high-risk for lymphoma.
Funder: National Cancer Institute
Principal Investigator: Habel, Laurel
ABC: Antidepressants and Breast Cancer Pharmacoepidemiology
The overarching goal of this project is to investigate the association between the concomitant use of SSRI and tamoxifen and the risk of recurrence or new primary breast cancer. We propose a population based case-control design nested within a cohort of women diagnosed with early stage hormone receptor positive breast cancer. We plan to assemble large a cohort of women with breast cancer using a SEER-affiliated electronic tumor registry and identify women who developed a recurrence or a new primary breast cancer (cases) & those who remained breast cancer-free (controls).
Funder: National Cancer Institute
Principal Investigator: Habel, Laurel
To examine the relationship between three prevalent mental health disorders (depression, anxiety disorders, and ADHD), their associated therapies, and outcomes for hypertension, atrial fibrillation and venous thromboembolic disease within the NHLBI-sponsored Cardiovascular Research Network (CVRN). These outcomes will include intermediate markers such as medication adherence and surrogate outcomes (e.g., systolic blood pressure and percentage of time spent at a therapeutic INR), as well as long-term clinical outcomes such as thromboembolic events (e.g., acute myocardial infarction, ischemic stroke, recurrent venous thromboembolism) and major bleeding.
The goal of this project is to compare the risk of cancer among users of glargine insulin to risk among users of other insulin (primary comparator drug will be NPH). The cohort study will be conducted among Kaiser health plan members who are in the KP Diabetes Registry. Information on medication use and covariates will be obtained from electronic records. The KP tumor registry will be used to capture information on cancer diagnoses. Cox proportional hazards modeling to compare risk of cancer at specific sites (10 most common) among glargine users to risk in users of NPH insulin, while adjusting for confounding variables.
Funder: Sanofi Pasteur
Principal Investigator: Habel, Laurel
TZD-Fibrate Feasibility Study
This proposal will explore the feasibility of a study to determine if combined use of a thiazolidinedione (PPAR- agonist) and a fibrate (PPAR- agonist) increase cardiovascular risk compared to thiazolidinedione use without fibrate.
Funder: Food and Drug Administration
Principal Investigator: Habel, Laurel
Propoxyphene Feasibility Study
The aim of this study is to explore the feasibility of a retrospective cohort study to evaluate the use of propoxyphene products in U.S. populations and the risk of death, fall-related fractures, and cardiotoxicity in new users of propoxyphene compared to new users of codeine and tramadol.
Funder: Food and Drug Administration
Principal Investigator: Habel, Laurel
Pharmaceuticals & Cancer (renewal)
The primary aim of this study is to continue surveillance of more than 200 of the most commonly prescribed drugs for carcinogenicity, as well as to examine selected drug-cancer associations of potential importance.
Funder: National Cancer Institute
Principal Investigator: Habel, Laurel
Building a Population Laboratory for Pharmaco-epidemiologic and Pharmacogenomic Studies in Cancer: Cardiotoxicity following Chemotherapy for Breast Cancer:
The primary aims of this project are to develop an infrastructure that will allow researchers to assess the validity of electronic data on chemotherapy infusion, including route of administration, drug and dosage in each participating site, and also to increase the availability and validity of electronic chemotherapy data among those sites with incomplete or inaccurate data.
Funder: National Cancer Institute
Principal Investigator: Habel, Laurel
Prophylactic Oophorectomy: Practice Patterns and Outcomes
This study aims to estimate the secular trends of prophylactic salpingo-oophorectomy by patient characteristics, examine practice patterns of prophylactic salpingo-oophorectomy by surgeon characteristics, and to estimate the risk of subsequent adnexal surgery after ovarian preservation.
Funder: National Institute on Aging
Principal Investigator: Habel, Laurel
Medications for ADHD and Risk of Serious Cardiovascular Disease in Adults: Addition of Stroke Endpoint
This study examines the risk of stroke associated with medications used to treat ADHD.
Funder: Food and Drug Administration
Principal Investigator: Habel, Laurel
Building a Population Laboratory for Pharmaco-epidemiologic and Pharmacogenomic Studies in Cancer: Cardiotoxicity Following Chemotherapy for Breast Cancer
This study aims to identify a cohort of patients with incident invasive breast cancer, and use the VDW and other electronic data sources to determine for each member of the cohort, among other things, the presence or absence of heart disease and other co-morbidities at the time of cancer diagnosis.
Funder: National Cancer Institute
Principal Investigator: Habel, Laurel
A Comparison of HER2 Positive and HER2 Negative Breast Cancer Patients
This study aims to estimate the age-specific incidence of HER2+ breast cancer in the Northern California Kaiser Permanente membership.
Funder: Genentech
Principal Investigator: Habel, Laurel
Comparative Study of Molecular Prognostic Signatures
The primary goals of this study are to evaluate the prognostic performance of HOXB13:IL17BR in ER+ lymph node-negative patients either untreated or treated with tamoxifen monotherapy; examine MGI as a molecular correlate of tumor grade; evaluate the prognostic performance of MGI in ER+ lymph node-negative patients either untreated or treated with tamoxifen monotherapy; and evaluate the added prognostic performance by combining HOXB13:IL17BR and MGI (MGI+HOXB13:IL17BR).
Funder: AviaraDx
Principal Investigator: Habel, Laurel
Epidemiology and Natural History of Herpes Zoster in Cancer Patients
The study estimates the incidence of herpes zoster (HZ) in patients diagnosed with cancer, especially those treated with immunosuppressive therapies.
Funder: Merck and Co., Inc.
Principal Investigator: Habel, Laurel
Proteomic Prediction of Breast Cancer Risk: A Cohort Study
This study tests the hypothesis that proteomic analysis of serum will identify proteins that are differentially expressed in women with breast cancer, and that are expressed prior to the clinical presentation of disease.
Funder: Department of Defense
Principal Investigator: Habel, Laurel
Association of PPAR Gamma Ligands and Colonic Neoplasia
This study assesses the potential association between a new class of diabetic drugs, thiazolidinediones (TZDs), and risk of colonic neoplasia among a population of individuals with type 2 diabetes mellitus.
Funder: National Cancer Institute
Principal Investigator: Habel, Laurel
A Multicenter, Observational Cohort Study... (ADHD Phase II)
The aim of this study is to examine whether medications used to treat ADHD are associated with risk of serious cardiovascular events in children and adults.
Funder: Agency for Healthcare Research and Quality
Principal Investigator: Habel, Laurel
Pharmaceuticals and Cancer - Surveillance Study
This project seeks to conduct surveillance of the 200 most commonly prescribed medications for their potential carcinogenic or chemopreventive effect and to conduct pilot studies on selected associations to determine if they deserve further investigation.
Funder: National Cancer Institute
Principal Investigator: Habel, Laurel
CRN II: Clinical and Pathologic Predictors of Recurrence after DCIS
This research aims to identify clinical and pathologic factors that can be used to more accurately identify DCIS patients at high and low risk for breast cancer recurrence.
Funder: National Cancer Institute
Principal Investigator: Habel, Laurel
Tumor Gene Expression and Breast Cancer Survival
This study examines whether a multi-gene assay can identify node-negative breast cancer patients at high or low risk for subsequent breast-cancer specific mortality.
Funder: Genomic Health, Inc.
Principal Investigator: Habel, Laurel